$WAT
Waters Corporation · NYSE · Healthcare
- Market cap
- 44.54B
- Volume
- 907.6K
- P/E
- 114.85
- Day range
- 447.29 – 456.20
- 52w range
- 282.77 – 465.36
- Analyst target
- 465.86
AI Summary
Generating a unique summary for WAT…
AI-generated for information only — not investment advice.
Share this ticker
$WAT -0.42% at 453.67 Terry Smith and 0 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/WAT
Company summary
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
Institutional ownership
Institutions hold 101.95% · insiders 0.10% · 1,632 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.48M | $3.85B | 8.64% | 2026-06-30 |
| Vanguard Capital Management LLC | 6.42M | $2.91B | 6.53% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 4.74M | $2.15B | 4.83% | 2026-06-30 |
| Massachusetts Financial Services Co. | 4.63M | $2.10B | 4.71% | 2026-06-30 |
| State Street Corporation | 4.38M | $1.99B | 4.46% | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 3.82M | $1.73B | 3.89% | 2026-06-30 |
| Invesco Ltd. | 3.49M | $1.59B | 3.56% | 2026-06-30 |
| Alliancebernstein L.P. | 2.69M | $1.22B | 2.74% | 2026-06-30 |
| Geode Capital Management, LLC | 2.64M | $1.20B | 2.68% | 2026-06-30 |
| Fundsmith LLP | 2.27M | $1.03B | 2.31% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| KUEBLER CHRISTOPHER A | Director | Sale at price 397.94 per share. | 3.6K | 2026-08-06 |
| KUEBLER CHRISTOPHER A | Director | Conversion of Exercise of derivative security at price 136.43 per share. | 3.6K | 2026-08-06 |
| JIANG WEI | Director | Stock Award(Grant) at price 0.00 per share. | 67.00 | 2026-06-30 |
| KNIGHT HEATHER | Director | Stock Award(Grant) at price 0.00 per share. | 63.00 | 2026-06-30 |
| JIANG WEI | Director | Stock Award(Grant) at price 0.00 per share. | 64.00 | 2026-03-31 |
| KNIGHT HEATHER | Director | Stock Award(Grant) at price 0.00 per share. | 68.00 | 2026-03-31 |
| JIANG WEI | Director | Purchase at price 289.46 per share. | 500.00 | 2026-03-16 |
| FEARON RICHARD H | Director | Purchase at price 306.34 per share. | 1.0K | 2026-03-06 |
| HUANG PEARL S. | Director | Stock Award(Grant) at price 0.00 per share. | 23.00 | 2026-02-25 |
| BENNETT JIANQING | Officer | Stock Award(Grant) at price 0.00 per share. | 986.00 | 2026-02-25 |
| JIANG WEI | Director | Stock Award(Grant) at price 0.00 per share. | 23.00 | 2026-02-25 |
| FRASER CLAIRE | Director | Stock Award(Grant) at price 0.00 per share. | 358.00 | 2026-02-25 |
Analyst ratings
Consensus score 1.61 (1 = strong buy, 5 = sell) · mean target 465.86
- TD CowenBuymain2026-10-13
- BarclaysOverweightmain2026-10-07
- GuggenheimBuymain2026-10-01
- Goldman SachsBuymain2026-09-21
- UBSBuyup2026-09-09
- Piper SandlerOverweightup2026-08-27
- CitigroupBuymain2026-08-10
- TD CowenBuyup2026-08-05
- RBC CapitalOutperformmain2026-08-05
- Evercore ISI GroupOutperformmain2026-08-05
Earnings
Next report: 2026-11-03
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 3.40 | 3.22 | 0.18 |
| 4Q2025 | 4.53 | 4.51 | 0.02 |
| 1Q2026 | 2.70 | 2.31 | 0.39 |
| 2Q2026 | 3.05 | 3.01 | 0.04 |
SEC filings
- 8-KCorporate Changes & Voting Matters2026-08-21Open
- 10-QPeriodic Financial Reports2026-08-11Open
- 8-KCorporate Changes & Voting Matters2026-08-04Open
- 11-KAnnual report of employee stock purchase2026-06-25Open
- SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-29Open
- 8-KCorporate Changes & Voting Matters2026-05-22Open
- 10-QPeriodic Financial Reports2026-05-12Open
- 8-KCorporate Changes & Voting Matters2026-05-05Open
- DEFA14AProxy Statements2026-04-09Open
- 8-KCorporate Changes & Voting Matters2026-03-23Open
Latest WAT news
- Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026.
Fri, 23 Oct 2026 12:00:00 +0000
- Waters (WAT) Stock Looks 26% Overvalued On Cash Flow Estimates
Waters Corporation has logged a powerful run in recent years, and the stock now sits at a level where investors naturally ask whether the current price is in line with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) view available, the question is how that cash flow based estimate stacks up against a share price that has already moved a long way. Over the past 3 years Waters has returned 77.7%, which puts real weight on getting the cash flow valuation call...
Wed, 21 Oct 2026 04:31:07 +0000
- Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows
WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.
Tue, 20 Oct 2026 13:20:00 +0000
- Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a collaboration intended to broaden access to clinically appropriate at-home cervical cancer screening through the FDA-cleared Onclarity™ Self-Collection Kit.1,2,13
Tue, 20 Oct 2026 12:00:00 +0000
- Earnings Preview: What to Expect From Waters Corporation’s Report
Waters Corporation is all geared up to release its third-quarter earnings next month, and analysts anticipate a double-digit boost in its profitability.
Mon, 19 Oct 2026 13:29:29 +0000
- IMU and UK Biobank to generate the world’s most detailed, large-scale picture of the human immune system for advancing research into health and disease
LONDON, October 19, 2026--IMU Biosciences (‘IMU or the ‘Company’), a biotechnology company using its High Definition Immunology™ platform to better understand the immune system and drive a shift in how we understand, diagnose, and treat disease, has today announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood samples collected from UK Biobank participants.
Mon, 19 Oct 2026 07:08:00 +0000
- Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation
Ultima Genomics, Inc., developer of ultra-high-throughput next-generation sequencing (NGS) platforms, today announced that its recently launched UG200 Sequencing Platform has been selected to power a new large-scale immune profiling study with IMU Biosciences and UK Biobank. The study will generate one of the most detailed pictures of the human immune system assembled to date, adding a high-resolution immune data layer and a foundational dataset for AI to UK Biobank, one of the world's most impo
Mon, 19 Oct 2026 07:05:00 +0000
- Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation (NYSE: WAT) today announced that it has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its informatics platform and has joined Anthropic's Model Hardware Standard (MHS) research program.
Tue, 13 Oct 2026 12:00:00 +0000